We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
BioNTech and OncoC4 have inked a deal that has BioNTech paying $200 million upfront to co-develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate as a monotherapy or combination therapy for various cancers. Read More
Johnson and Johnson (J&J) and Janssen Biotech have agreed to pay $25 million to settle a class action lawsuit alleging they violated antitrust laws in marketing their blockbuster drug anti-inflammatory drug Remicade (infliximab). Read More
Novo Nordisk will cut the U.S. list price of multiple insulin products by up to 75 percent, following rival Eli Lilly’s announcement of a similar price cut earlier this month.
A federal appeals court has ruled in favor of Gilead Sciences, rejecting the Regents of the University of Minnesota’s claim the drugmaker violated the university’s patent protections for sofosbuvir, a Hepatitis C antiviral branded as Sovaldi, among others.
Genentech has filed a complaint against Biogen seeking patent royalties from a manufacturing process Biogen allegedly used to produce its multiple sclerosis (MS) drug Tysabri (natalizumab). Read More
Drugmakers and others in the pharmaceutical supply chain still have much overhauling of shipping and verification systems and processes to do if they are to meet the Nov. 27 deadline for Drug Supply Chain Security Act (DSCSA) compliance, a new report says. Read More